Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) recently highlighted clinical research efforts in oncology and viral hepatitis that demonstrate its commitment to novel diagnostic capabilities and unique bioinformatics resources to enhance patient care in today’s rapidly evolving healthcare system.
Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) recently announced the completion of its acquisition of Covance Inc., following its entry into a definitive purchase agreement on November 2, 2014. At closing, the purchase consideration was valued at $107.19 per Covance share, consisting of $75.76 in cash and 0.2686 LabCorp shares for each Covance share, or an equity value of approximately $6.2 billion and an enterprise value of approximately $5.7 billion. This combination creates the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end solutions for drug and diagnostics development and commercialization.
Research Documents Rapid Detection of Structural Variation in a Human Genome Using BioNano’s Irys System
BioNano Genomics, Inc., the leader in genome mapping, and BGI, the world’s largest genomics organization, highlight the publication of a peer-reviewed research article and its accompanying data* in GigaScience. This article describes the rapid detection of structural variation in a human genome using the high-throughput, cost-effective genome mapping technology of the Irys® System. Structural variations are known to play an important role in human genetic diversity and disease susceptibility. However, comprehensive, efficient and unbiased discovery of structural variations has previously not been possible through next generation sequencing (NGS) and DNA arrays with their inherent technology limitations.
Following NICE’s Exclusive Recommendation, NHS England Agrees to Access Program for Oncotype DX Breast Cancer Test
Genomic Health, Inc. (Nasdaq: GHDX) recently announced that, as of April 1, 2015, the Oncotype DX® test will be available to eligible breast cancer patients through the National Health Service (NHS) in England as the only multi-gene breast cancer test recommended by the National Institute for Health and Care Excellence (NICE) for use as an option to assist in chemotherapy treatment decision-making.
PDI, Inc. Subsidiary Interpace Diagnostics Announces PancraGen™ Benefits Reinforced in Pivotal Study Published in Endoscopy
PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, recently announced the publication of results of the pivotal PancraGen™ multicenter clinical validation study in the February 2015 issue of Endoscopy. The study concluded that PancraGen (formerly PathFinderTG®-Pancreas) is 90% accurate at predicting benign and malignant disease in patients with pancreatic cysts, providing important insights into patients’ likelihood of pancreatic cancer. These results provide support for using PancraGen to provide more informed management decisions for patients with pancreatic cysts, including whether surgery or surveillance is the most appropriate approach.